Agios Net Working Capital from 2010 to 2026

AGIO Stock  USD 28.73  0.93  3.35%   
Agios Pharm Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 736.5 M. During the period from 2010 to 2026, Agios Pharm Net Working Capital quarterly data regression pattern had sample variance of 61539.1 T and median of  518,818,000. View All Fundamentals
 
Net Working Capital  
First Reported
2020-03-31
Previous Quarter
949.1 M
Current Value
958.4 M
Quarterly Volatility
387.6 M
 
Covid
Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharm's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 15.4 M or Selling General Administrative of 189.3 M, as well as many indicators such as Price To Sales Ratio of 34.59, Dividend Yield of 0.0 or PTB Ratio of 1.32. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.
  
Build AI portfolio with Agios Stock
Check out the analysis of Agios Pharm Correlation against competitors.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Latest Agios Pharm's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Agios Pharm over the last few years. It is Agios Pharm's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharm's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Agios Net Working Capital Regression Statistics

Arithmetic Mean562,496,999
Geometric Mean516,001,339
Coefficient Of Variation44.10
Mean Deviation212,179,880
Median518,818,000
Standard Deviation248,070,822
Sample Variance61539.1T
Range666.8M
R-Value0.86
Mean Square Error17112.2T
R-Squared0.74
Slope42,239,500
Total Sum of Squares984626.1T

Agios Net Working Capital History

2026736.5 M
2025B
2024884.4 M
2023765.9 M
2022770.1 M
2021B
2020542.3 M

About Agios Pharm Financial Statements

Agios Pharm investors utilize fundamental indicators, such as Net Working Capital, to predict how Agios Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working CapitalB736.5 M

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with Agios Stock

  0.82LIPO Lipella PharmaceuticalsPairCorr

Moving against Agios Stock

  0.87JNJ Johnson Johnson Earnings Call This WeekPairCorr
  0.81WSFS WSFS FinancialPairCorr
  0.72ACN Accenture plcPairCorr
  0.72CSCO Cisco SystemsPairCorr
  0.7TRV The Travelers Companies Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out the analysis of Agios Pharm Correlation against competitors.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.01)
Revenue Per Share
0.777
Quarterly Revenue Growth
0.437
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.